Influence of the semiconductive material on space charge build-up in extruded HVDC cables

U. Nilsson,J. Bostrom

DOI: https://doi.org/10.1109/ELINSL.2010.5549811

2010-06-06

Abstract:The paper discuss means to reduce the space charge accumulation in polymeric HVDC cables by optimising the composition of the semiconductive material used in the conductor and insulation screens.

What problem does this paper attempt to address?

Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain

Jinxuan Ren,Jiaqi Lin,Lina Yu,Min Yan

DOI: https://doi.org/10.3390/ijms23158274

IF: 5.6

2022-01-01

International Journal of Molecular Sciences

Abstract:The bioactive lipid lysophosphatidylcholine (LPC), a major phospholipid component of oxidized low-density lipoprotein (Ox-LDL), originates from the cleavage of phosphatidylcholine by phospholipase A2 (PLA2) and is catabolized to other substances by different enzymatic pathways. LPC exerts pleiotropic effects mediated by its receptors, G protein-coupled signaling receptors, Toll-like receptors, and ion channels to activate several second messengers. Lysophosphatidylcholine (LPC) is increasingly considered a key marker/factor positively in pathological states, especially inflammation and atherosclerosis development. Current studies have indicated that the injury of nervous tissues promotes oxidative stress and lipid peroxidation, as well as excessive accumulation of LPC, enhancing the membrane hyperexcitability to induce chronic pain, which may be recognized as one of the hallmarks of chronic pain. However, findings from lipidomic studies of LPC have been lacking in the context of chronic pain. In this review, we focus in some detail on LPC sources, biochemical pathways, and the signal-transduction system. Moreover, we outline the detection methods of LPC for accurate analysis of each individual LPC species and reveal the pathophysiological implication of LPC in chronic pain, which makes it an interesting target for biomarkers and the development of medicine regarding chronic pain.
The Formation of Phosphatidylcholine Oxidation Products by Stimulated Phagocytes

Andreas Jerlich,R. Jörg Schaur,Andrew R. Pitt,Corinne M. Spickett

DOI: https://doi.org/10.1080/1071576031000091720

IF: 4.2878

2003-06-01

Free Radical Research

Abstract:Phagocytic cells produce a variety of oxidants as part of the immune defence, which react readily both with proteins and lipids, and could contribute to the oxidation of low density lipoprotein in atherosclerosis. We have investigated the oxidation of phospholipid vesicles by neutrophils and mononuclear cells, to provide a model of lipid oxidation in the absence of competing protein. Phorbol 12-myristate 13-acetate-stimulated neutrophils were incubated with phospholipid vesicles containing dipalmitoyl phosphatidylcholine, palmitoyl-arachidonoyl phosphatidylcholine (PAPC) and stearoyl-oleoyl phosphatidylcholine, before extraction of the lipids for analysis by HPLC coupled to electrospray mass spectrometry. The formation of monohydroperoxides (814 m/z) and bishydroperoxides (846 m/z) of PAPC was observed. However, the major oxidized product occurred at 828 m/z,and was identified as 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphocholine. These products were also formed in incubations where the neutrophils were replaced by mononuclear cells, and the amounts produced per million cells were similar. These results show that following oxidative attack by phagocytes stimulated by PMA, intact phospholipid oxidation products can be detected. The identification of an epoxyisoprostane phospholipid as the major product of phagocyte-induced phospholipid oxidation is novel, and in view of its inflammatory properties has implications for phagocyte involvement in atherogenesis.

biochemistry & molecular biology
An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

Shi-Hui Law,Mei-Lin Chan,Gopal K. Marathe,Farzana Parveen,Chu-Huang Chen,Liang-Yin Ke

DOI: https://doi.org/10.3390/ijms20051149

IF: 5.6

2019-03-06

International Journal of Molecular Sciences

Abstract:Lysophosphatidylcholine (LPC) is increasingly recognized as a key marker/factor positively associated with cardiovascular and neurodegenerative diseases. However, findings from recent clinical lipidomic studies of LPC have been controversial. A key issue is the complexity of the enzymatic cascade involved in LPC metabolism. Here, we address the coordination of these enzymes and the derangement that may disrupt LPC homeostasis, leading to metabolic disorders. LPC is mainly derived from the turnover of phosphatidylcholine (PC) in the circulation by phospholipase A2 (PLA2). In the presence of Acyl-CoA, lysophosphatidylcholine acyltransferase (LPCAT) converts LPC to PC, which rapidly gets recycled by the Lands cycle. However, overexpression or enhanced activity of PLA2 increases the LPC content in modified low-density lipoprotein (LDL) and oxidized LDL, which play significant roles in the development of atherosclerotic plaques and endothelial dysfunction. The intracellular enzyme LPCAT cannot directly remove LPC from circulation. Hydrolysis of LPC by autotaxin, an enzyme with lysophospholipase D activity, generates lysophosphatidic acid, which is highly associated with cancers. Although enzymes with lysophospholipase A1 activity could theoretically degrade LPC into harmless metabolites, they have not been found in the circulation. In conclusion, understanding enzyme kinetics and LPC metabolism may help identify novel therapeutic targets in LPC-associated diseases.

biochemistry & molecular biology,chemistry, multidisciplinary
Lysophosphatidylcholine is a Major Component of Platelet Microvesicles Promoting Platelet Activation and Reporting Atherosclerotic Plaque Instability

Philipp Diehl,Frederik Nienaber,Maria Zaldivia,Johannes Stamm,Patrick Siegel,Natalie Mellett,Marius Wessinger,Xiaowei Wang,James McFadyen,Nicole Bassler,Gerhard Puetz,Nay Htun,David Braig,Jonathon Habersberger,Thomas Helbing,Steffen Eisenhardt,Maria Fuller,Christoph Bode,Peter Meikle,Yung Chen,Karlheinz Peter,Maria T. K. Zaldivia,Patrick M. Siegel,Natalie A. Mellett,James D. McFadyen,Nay M. Htun,Steffen U. Eisenhardt,Peter J. Meikle,Yung Chih Chen

DOI: https://doi.org/10.1055/s-0039-1683409

2019-08-01

Thrombosis and Haemostasis

Abstract:Background Microvesicles (MVs) are small cell-derived vesicles, which are mainly released by activated cells. They are part of a communication network delivering biomolecules, for example, inflammatory molecules, via the blood circulation to remote cells in the body. Platelet-derived MVs are known to induce vascular inflammation. Research on the mediators and mechanisms of their inflammatory effects has attracted major interest. We hypothesize that specific lipids are the mediators of vascular inflammation caused by platelet-derived MVs. Methods and Results Liquid chromatography electrospray ionization–tandem mass spectrometry was used for lipid profiling of platelet-derived MVs. Lysophosphatidylcholine (LPC) was found to be a major component of platelet-derived MVs. Investigating the direct effects of LPC, we found that it induces platelet activation, spreading, migration and aggregation as well as formation of inflammatory platelet–monocyte aggregates. We show for the first time that platelets express the LPC receptor G2AR, which mediates LPC-induced platelet activation. In a mouse model of atherosclerotic plaque instability/rupture, circulating LPC was detected as a surrogate marker of plaque instability. These findings were confirmed by matrix-assisted laser desorption ionization imaging, which showed that the LPC concentration of human plaques was highest in vulnerable plaque regions. Conclusion LPC is a major component of platelet-derived MVs and via its interaction with G2AR on platelets contributes to platelet activation, spreading, migration and aggregation and ultimately to vascular inflammation. Circulating LPC reports on atherosclerotic plaque instability in mice and is significantly increased in unstable areas of atherosclerotic plaques in both mice and humans, linking LPC to plaque instability.

peripheral vascular disease,hematology
Lysophospholipids and Their Receptors Serve As Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury.

Ying Shao,Gayani Nanayakkara,Jiali Cheng,Ramon Cueto,William Y. Yang,Joon-Young Park,Hong Wang,Xiaofeng Yang

DOI: https://doi.org/10.1089/ars.2017.7069

2017-01-01

Antioxidants and Redox Signaling

Abstract:Significance: We proposed lysophospholipids (LPLs) and LPL-G-protein-coupled receptors (GPCRs) as conditional danger-associated molecular patterns (DAMPs) and conditional DAMP receptors as a paradigm shift to the widely accepted classical DAMP and DAMP receptor model. Recent Advances: The aberrant levels of LPLs and GPCRs activate pro-inflammatory signal transduction pathways, trigger innate immune response, and lead to tissue oxidative and inflammatory injury. Critical Issues: Classical DAMP model specifies only the endogenous metabolites that are released from damaged/dying cells as DAMPs, but fails to identify elevated endogenous metabolites secreted from viable/live cells during pathologies as DAMPs. The current classification of DAMPs also fails to clarify the following concerns: (i) Are molecules, which bind to pattern recognition receptors (PRRs), the only DAMPs contributing to inflammation and tissue injury? (ii) Are all DAMPs acting only via classical PRRs during cellular stress? To answer these questions, we reviewed the molecular characteristics and signaling mechanisms of LPLs, a group of endogenous metabolites and their specific receptors and analyzed the significant progress achieved in characterizing oxidative stress mechanisms of LPL mediated tissue injury. Future Directions: Further LPLs and LPL-GPCRs may serve as potential therapeutic targets for the treatment of pathologies induced by sterile inflammation.
Research progress, challenges and perspectives of phospholipids metabolism in the LXR‐LPCAT3 signaling pathway and its relation to NAFLD (Review)

Junmin Wang,Jiacheng Li,Yugang Fu,Yingying Zhu,Liubing Lin,Yong Li

DOI: https://doi.org/10.3892/ijmm.2024.5356

IF: 5.314

2024-02-12

International Journal of Molecular Medicine

Abstract:Phospholipids (PLs) are principle constituents of biofilms, with their fatty acyl chain composition significantly impacting the biophysical properties of membranes, thereby influencing biological processes. Recent studies have elucidated that fatty acyl chains, under the enzymatic action of lyso‑phosphatidyl‑choline acyltransferases (LPCATs), expedite incorporation into the sn‑2 site of phosphatidyl‑choline (PC), profoundly affecting pathophysiology. Accumulating evidence suggests that alterations in LPCAT activity are implicated in various diseases, including non‑alcoholic fatty liver disease (NAFLD), hepatitis C, atherosclerosis and cancer. Specifically, LPCAT3 is instrumental in maintaining systemic lipid homeostasis through its roles in hepatic lipogenesis, intestinal lipid absorption and lipoprotein secretion. The liver X receptor (LXR), pivotal in lipid homeostasis, modulates cholesterol, fatty acid (FA) and PL metabolism. LXR's capacity to modify PL composition in response to cellular sterol fluctuations is a vital mechanism for protecting biofilms against lipid stress. Concurrently, LXR activation enhances LPCAT3 expression on cell membranes and elevates polyunsaturated PL levels. This activation can ameliorate saturated free FA effects in vitro or endoplasmic reticulum stress in vivo due to lipid accumulation in hepatic cells. Pharmacological interventions targeting LXR, LPCAT and membrane PL components could offer novel therapeutic directions for NAFLD management. The present review primarily focused on recent advancements in understanding the LPCAT3 signaling pathway's role in lipid metabolism related to NAFLD, aiming to identify new treatment targets for the disease.

medicine, research & experimental
Phospholipase D: a lipid centric review

G. M. Jenkins,M. A. Frohman

DOI: https://doi.org/10.1007/s00018-005-5195-z

IF: 8

2005-09-07

Cellular and Molecular Life Sciences

Abstract:Abstract.Phospholipase D (PLD) hydrolyzes the phosphodiester bond of the glycerolipid phosphatidylcholine, resulting in the production of phosphatidic acid and free choline. Phosphatidic acid is widely considered to be the intracellular lipid mediator of many of the biological functions attributed to PLD. However, phosphatidic acid is a tightly regulated lipid in cells and can be converted to other potentially bioactive lipids, including diacylglycerol and lysophosphatidic acid. PLD activities have been described in multiple organisms, including plants, mammals, bacteria and yeast. In mammalian systems, PLD activity regulates the actin cytoskeleton, vesicle trafficking for secretion and endocytosis, and receptor signaling. PLD is in turn regulated by phosphatidylinositol-4,5-bisphosphate, protein kinase C and ADP Ribosylation Factor and Rho family GTPases. This review focuses on the lipid precursors and products of mammalian PLD metabolism, especially phosphatidic acid and the roles this lipid performs in the mediation of the functions of PLD.

cell biology,biochemistry & molecular biology
Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease

Ying Zhou,Peter J. Little,Hang T. Ta,Suowen Xu,Danielle Kamato

DOI: https://doi.org/10.1016/j.pharmthera.2019.107404

IF: 13.4

2019-01-01

Pharmacology & Therapeutics

Abstract:Lysophosphatidic acid (LPA) is a collective name for a set of bioactive lipid species. Via six widely distributed G protein-coupled receptors (GPCRs), LPA elicits a plethora of biological responses, contributing to inflammation, thrombosis and atherosclerosis. There have recently been considerable advances in GPCR signaling especially recognition of the extended role for GPCR transactivation of tyrosine and serine/threonine kinase growth factor receptors. This review covers LPA signaling pathways in the light of new information. The use of transgenic and gene knockout animals, gene manipulated cells, pharmacological LPA receptor agonists and antagonists have provided many insights into the biological significance of LPA and individual LPA receptors in the progression of atherosclerosis and vascular diseases. This review provides a comprehensive presentation of LPA with the highlight of the distinct role of its receptors in cell and animal models that relate to atherosclerosis and vascular diseases, and therefore provides new opportunities to reduce the burden of cardiovascular diseases. The recent drug development strategies that target LPA signaling pathways are also included in this review.
Involvement of Lysophospholipids in Pulmonary Vascular Functions and Diseases

Hiroaki Kume,Rina Harigane,Mami Rikimaru

DOI: https://doi.org/10.3390/biomedicines12010124

IF: 4.757

2024-01-09

Biomedicines

Abstract:Extracellular lysophospholipids (lysophosphatidic acid, lysophosphatidylcholine, sphingosine 1-phosphate, etc.), which are synthesized from phospholipids in the cell membrane, act as lipid mediators, and mediate various cellular responses in constituent cells in the respiratory system, such as contraction, proliferation, migration, and cytoskeletal organization. In addition to these effects, the expression of the adhesion molecules is enhanced by these extracellular lysophospholipids in pulmonary endothelial cells. These effects are exerted via specific G protein-coupled receptors. Rho, Ras, and phospholipase C (PLC) have been proven to be their signaling pathways, related to Ca2+ signaling due to Ca2+ dynamics and Ca2+ sensitization. Therefore, lysophospholipids probably induce pulmonary vascular remodeling through phenotype changes in smooth muscle cells, endothelial cells, and fibroblasts, likely resulting in acute respiratory distress syndrome due to vascular leak, pulmonary hypertension, and pulmonary fibrosis. Moreover, lysophospholipids induce the recruitment of inflammatory cells to the lungs via the enhancement of adhesion molecules in endothelial cells, potentially leading to the development of asthma. These results demonstrate that lysophospholipids may be novel therapeutic targets not only for injury, fibrosis, and hypertension in the lung, but also for asthma. In this review, we discuss the mechanisms of the effects of lysophospholipids on the respiratory system, and the possibility of precision medicine targeting lysophospholipids as treatable traits of these diseases.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Lysophosphatidylcholine facilitates the pathogenesis of psoriasis through activating keratinocytes and T cells differentiation via glycolysis

Panpan Liu,Youyou Zhou,Chao Chen,Bei Yan,Lei Li,Wu Zhu,Jie Li,Mingliang Chen,Juan Su,Yehong Kuang,Xiang Chen,Cong Peng

DOI: https://doi.org/10.1111/jdv.19088

2023-04-18

Journal of the European Academy of Dermatology and Venereology

Abstract:BACKGROUND: Although abnormal metabolism plays a critical role in the pathogenesis of psoriasis, the details are unclear.OBJECTIVES: Here, we identified to explore the role and mechanism of lysophosphatidylcholine (LPC) on the pathogenesis of psoriasis.METHODS: The level of LPC in plasma and skin lesions and the expression of G2A on skin lesions of psoriasis patients were detected by enzyme-linked immunosorbent assay, liquid chromatography-tandem mass spectrometry, or immunohistochemistry, respectively. The glycolysis in the skin lesions of imiquimod (IMQ)-induced psoriasis-like mouse model was detected by extracellular acidification rate. LPC was subcutaneously injected into IMQ-treated mouse ears, and the phenotype as well as the glycolysis were evaluated. Exploring the effects and mechanism of LPC on keratinocytes and CD4+ T cells by culturing primary keratinocytes and CD4+ T in vitro.RESULTS: We found that LPC was significantly increased both in the plasma and skin lesions of psoriatic patients, while G2A, exerting an essential role in LPC-inducing biological functions, was increased in psoriatic lesions. The abundance of LPC was positively correlated with glycolytic activity in the psoriasis-like mouse model. LPC treatment facilitated psoriasis-like inflammation and glycolytic activity in skin lesions. Mechanistically, the LPC/G2A axis significantly triggered glycolytic activity and produced inflammatory factors in keratinocytes, and blockade of glycolysis abrogated LPC-induced expression of inflammatory mediators in keratinocytes. LPC activated STAT1, resulting in recognition and binding to the promoters of GCK and PKLR, which are glycolytic rate-limiting enzymes. Furthermore, the LPC/G2A axis directly benefited Th1 differentiation, which was dependent on LPC-induced glycolytic activity. Notably, LPC indirectly facilitated Th17 differentiation by inducing the secretion of IL-1β in keratinocytes-T cells coculture system.CONCLUSIONS: Taken together, our findings revealed the role of the LPC/G2A axis in the pathogenesis of psoriasis; targeting LPC/G2A is a potential strategy for psoriasis therapy.

dermatology
Phospholipid metabolism in health and disease

Takao Shimizu

DOI: https://doi.org/10.1254/jpssuppl.wcp2018.0_cl-31

2018-01-01

Proceedings for Annual Meeting of The Japanese Pharmacological Society

Abstract:Glycerophospholipids (phospholipids) are a major constituent of biological membrane, pulmonary surfactant lipids or precursors of bioactive lipid mediators. More than 1,000 different species in terms of fatty acid distribution, polar head groups, and linkage between glycerol backbone and fatty acyl moiety (1). Mechanism how these diversity is made, and biological output of the individual or mixed fatty acyl species remain to be fully elucidated. By molecular cloning of acyltransferases in the last decade by our group and others, we propose a new model how the diversity is made. Palmitic acid (16:0), oleic acid (18:1) and arachidonic acid (20:4) are accumulated by Lands' cycle (remodeling pathway, lysoPC to PC), while surprisingly, linoleic acid (18:2) and docosahexaenoic acid (22:6) are enriched by Kennedy pathway (Lyso-PA to PA) (2). To confirm the proposed model, we have established mice and cell lines which genetically lack one or two enzymes responsible for these reactions. We confirmed that DPPC (16:0/16:0) is produced by a Lands'enzyme, LPCAT1, which is critical for surfactant formation and pulmonary functions (2). Similarly, we found that LPCAT3, another Lands'enzyme is pivotal for formation of arachidonate-rich membrane that is related to lipoprotein formation, independent of eicosanoid synthesis (3). DHA is incorporated into phospholipid membrane in testis and retina, and loss of DHA-membrane is associated with male infertility and retinal dysfunctions (4, 5). While the molecular mechanism underlying the roles and mouse phenotypes are unclear, phospholipids with different fatty acyl species play unique and essential roles in health and disease over the just barrier functions. Supported by MEXT, AMED, and Takeda Science Foundation. The laboratory at the U-Tokyo funded by Shimadzu, Co., Ltd, and NCGM laboratory is partly supported by ONO Pharmaceutical.Ref.1. Shimizu, T. (2009) Ann. Rev. Pharmacol. Toxicol. 49, 123-150.2. Harayama, T. et al. (2014) Cell Metabolism 20, 295-3053. Hashidate-Yoshida, T. Harayama, T. et al. (2015) eLife 063284. Shindou, H. et al. (2017) J. Biol. Chem. 292, 12054-120645. Iizuka-Hishikawa, Y. et al. (2017) J. Biol. Chem. 292, 12065-12076
The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum

G. Mackenzie,P. Jenner,C. Marsden

DOI: https://doi.org/10.1016/0306-4522(94)00621-B

IF: 3.708

1995-07-01

Neuroscience

Abstract:
Lysophosphatidylcholine induces cytotoxicity/apoptosis and IL-8 production of human endothelial cells: Related mechanisms

Mei-Chi Chang,Jang-Jaer Lee,Yi-Jane Chen,Szu-I Lin,Li-Deh Lin,Eric Jein-Wen Liou,Wei-Ling Huang,Chiu-Po Chan,Chi-Chia Huang,Jiiang-Huei Jeng

DOI: https://doi.org/10.18632/oncotarget.22425

2017-11-10

Oncotarget

Abstract:Increased levels of oxidized low-density lipoprotein oxLDL) are shown to elevate the risk of cardiovascular diseases such as atherosclerosis, thrombosis, stroke, and myocardial infarction. This is possibly due to the toxic effects of oxLDLs on vascular cells. Various oxLDLs including lysophosphatidylcholine (LPC) and 7-ketocholesterol injure vascular endothelial cells and stimulate inflammatory reaction. However the toxicity of LPC on endothelial cells is not clear. In this study, human endothelial cells were exposed to LPC. Cytotoxicity was measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. Propidium iodide (PI) staining or PI/Annexin V dual staining flow cytometry were used to determine cell cycle progression and apoptosis. Reactive oxygen species (ROS) level was analyzed by DCFH-DA labeling flow cytometry. RNA and protein expression of endothelial cells was studied by reverse transcriptase-polymerase chain reaction and western blotting. IL-8 secretion was measured by enzyme-linked immunosorbant assay. LPC showed cytotoxicity to endothelial cells (>50 µg/ml). LPC induced cell cycle arrest and apoptosis with concomitant inhibition of cdc2 and cyclin B1 expression. LPC stimulated intracellular ROS production and ATM/Chk2, ATR/Chk1 and Akt activation. IL-8 expression and secretion in endothelial cells were induced by LPC. LPC-induced apoptosis, and IL-8 expression/secretion was attenuated by LY294002, a PI3K/Akt inhibitor. These results reveal that LPC is involved in the pathogenesis of atherosclerosis and vascular diseases by stimulation of inflammation and injury to endothelial cells. These events are related to ROS, ATM/Chk2, ATR/Chk2 and PI3K/Akt signaling. Understanding the toxic mechanisms of LPC is useful for future prevention and treatment atherosclerosis.
Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis

Marlies Schippers,Eduard Post,Ilse Eichhorn,Jitske Langeland,Leonie Beljaars,Madhu S. Malo,Richard A. Hodin,José Luis Millán,Yury Popov,Detlef Schuppan,Klaas Poelstra

DOI: https://doi.org/10.3390/cells9122708

IF: 6

2020-12-17

Cells

Abstract:Alkaline phosphatase (AP) activity is highly upregulated in plasma during liver diseases. Previously, we demonstrated that AP is able to detoxify lipopolysaccharide (LPS) by dephosphorylating its lipid A moiety. Because a role of gut-derived LPS in liver fibrogenesis has become evident, we now examined the relevance of phosphate groups in the lipid A moiety in this process. The effects of mono-phosphoryl and di-phosphoryl lipid A (MPLA and DPLA, respectively) were studied in vitro and LPS-dephosphorylating activity was studied in normal and fibrotic mouse and human livers. The effects of intestinal AP were studied in mice with CCL4-induced liver fibrosis. DPLA strongly stimulated fibrogenic and inflammatory activities in primary rat hepatic stellate cells (rHSCs) and RAW264.7 macrophages with similar potency as full length LPS. However, MPLA did not affect any of the parameters. LPS-dephosphorylating activity was found in mouse and human livers and was strongly increased during fibrogenesis. Treatment of fibrotic mice with intravenous intestinal-AP significantly attenuated intrahepatic desmin+− and αSMA+ −HSC and CD68+− macrophage accumulation. In conclusion, the lack of biological activity of MPLA, contrasting with the profound activities of DPLA, shows the relevance of LPS-dephosphorylating activity. The upregulation of LPS-dephosphorylating activity in fibrotic livers and the protective effects of exogenous AP during fibrogenesis indicate an important physiological role of intestinal-derived AP during liver fibrosis.

cell biology
The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles

Shibbir Ahmed Khan,Marc A. Ilies

DOI: https://doi.org/10.3390/ijms24021353

IF: 5.6

2023-01-10

International Journal of Molecular Sciences

Abstract:The phospholipase A2 (PLA2) superfamily of phospholipase enzymes hydrolyzes the ester bond at the sn-2 position of the phospholipids, generating a free fatty acid and a lysophospholipid. The PLA2s are amphiphilic in nature and work only at the water/lipid interface, acting on phospholipid assemblies rather than on isolated single phospholipids. The superfamily of PLA2 comprises at least six big families of isoenzymes, based on their structure, location, substrate specificity and physiologic roles. We are reviewing the secreted PLA2 (sPLA2), cytosolic PLA2 (cPLA2), Ca2+-independent PLA2 (iPLA2), lipoprotein-associated PLA2 (LpPLA2), lysosomal PLA2 (LPLA2) and adipose-tissue-specific PLA2 (AdPLA2), focusing on the differences in their structure, mechanism of action, substrate specificity, interfacial kinetics and tissue distribution. The PLA2s play important roles both physiologically and pathologically, with their expression increasing significantly in diseases such as sepsis, inflammation, different cancers, glaucoma, obesity and Alzheimer’s disease, which are also detailed in this review.

biochemistry & molecular biology,chemistry, multidisciplinary
Characterization of Lysophospholipase D Activity in Mammalian Cell Membranes

Yuhuan Xie,Krishna M. Ella,Terra C. Gibbs,Marianne E. Yohannan,Stewart M. Knoepp,Pravita Balijepalli,G. Patrick Meier,Kathryn E. Meier

DOI: https://doi.org/10.3390/cells13060520

IF: 6

2024-03-17

Cells

Abstract:Lysophosphatidic acid (LPA) is a lipid mediator that binds to G-protein-coupled receptors, eliciting a wide variety of responses in mammalian cells. Lyso-phospholipids generated via phospholipase A2 (PLA2) can be converted to LPA by a lysophospholipase D (lyso-PLD). Secreted lyso-PLDs have been studied in more detail than membrane-localized lyso-PLDs. This study utilized in vitro enzyme assays with fluorescent substrates to examine LPA generation in membranes from multiple mammalian cell lines (PC12, rat pheochromocytoma; A7r5, rat vascular smooth muscle; Rat-1, rat fibroblast; PC-3, human prostate carcinoma; and SKOV-3 and OVCAR-3, human ovarian carcinoma). The results show that membranes contain a lyso-PLD activity that generates LPA from a fluorescent alkyl-lyso-phosphatidylcholine, as well as from naturally occurring acyl-linked lysophospholipids. Membrane lyso-PLD and PLD activities were distinguished by multiple criteria, including lack of effect of PLD2 over-expression on lyso-PLD activity and differential sensitivities to vanadate (PLD inhibitor) and iodate (lyso-PLD inhibitor). Based on several lines of evidence, including siRNA knockdown, membrane lyso-PLD is distinct from autotaxin, a secreted lyso-PLD. PC-3 cells express GDE4 and GDE7, recently described lyso-PLDs that localize to membranes. These findings demonstrate that membrane-associated lyso-D activity, expressed by multiple mammalian cell lines, can contribute to LPA production.

cell biology
Modified phospholipids as anti-inflammatory compounds

Erez Feige,Itzhak Mendel,Jacob George,Niva Yacov,Dror Harats

DOI: https://doi.org/10.1097/MOL.0b013e32833f2fcb

Abstract:Purpose of review: Oxidized phospholipids (OxPLs) are abundantly found at sites of inflammation and are considered to play an active role in the modulation of the immune response. Whereas most studies attributed a proinflammatory role to OxPLs, recent studies demonstrate that some products of phospholipid oxidation may in fact exhibit anti-inflammatory properties. This study summarizes the proinflammatory and anti-inflammatory properties of OxPLs and sheds light on the therapeutic potential of OxPL derivatives or analogs for treatment of chronic inflammatory disorders. Recent findings: OxPLs may inhibit activation of several Toll-like receptors and can epigenetically reduce the capacity of dendritic cells to function as mature, fully functional immunostimulatory cells. These data demonstrate that OxPLs can induce anti-inflammatory effects. Moreover, VB-201, an orally available synthetic phospholipid analog of the Lecinoxoid family, was found to attenuate inflammation in various preclinical animal models and is currently employed in a phase II clinical trial in psoriasis. Summary: Chemical or biological modifications of phospholipids yield various products, some of which may exhibit anti-inflammatory properties. Identification of such species and generation of more stable/potent anti-inflammatory OxPL variants may represent a novel approach for the treatment of immune-mediated diseases such as psoriasis, atherosclerosis, multiple sclerosis and rheumatoid arthritis.
Phosphatidylserine-specific phospholipase A1: A friend or the devil in disguise

Yang Zhao,Stephan Hasse,Sylvain G Bourgoin

DOI: https://doi.org/10.1016/j.plipres.2021.101112

Abstract:Various human tissues and cells express phospholipase A1 member A (PLA1A), including the liver, lung, prostate gland, and immune cells. The enzyme belongs to the pancreatic lipase family. PLA1A specifically hydrolyzes sn-1 fatty acid of phosphatidylserine (PS) or 1-acyl-lysophosphatidylserine (1-acyl-lysoPS). PS externalized by activated cells or apoptotic cells or extracellular vesicles is a potential source of substrate for the production of unsaturated lysoPS species by PLA1A. Maturation and functions of many immune cells, such as T cells, dendritic cells, macrophages, and mast cells, can be regulated by PLA1A and lysoPS. Several lysoPS receptors, including GPR34, GPR174 and P2Y10, have been identified. High serum levels and high PLA1A expression are associated with autoimmune disorders such as Graves' disease and systemic lupus erythematosus. Increased expression of PLA1A is associated with metastatic melanomas. PLA1A may contribute to cardiometabolic disorders through mediating cholesterol transportation and producing lysoPS. Furthermore, PLA1A is necessary for hepatitis C virus assembly and can play a role in the antivirus innate immune response. This review summarizes recent findings on PLA1A expression, lysoPS and lysoPS receptors in autoimmune disorders, cancers, cardiometabolic disorders, antivirus immune responses, as well as regulations of immune cells.
Production of Extracellular Lysophosphatidic Acid in the Regulation of Adipocyte Functions and Liver Fibrosis

Fang Yang,Guo-Xun Chen

DOI: https://doi.org/10.3748/wjg.v24.i36.4132

IF: 5.374

2018-01-01

World Journal of Gastroenterology

Abstract:Lysophosphatidic acid (LPA), a glycerophospholipid, consists of a glycerol backbone connected to a phosphate head group and an acyl chain linked to sn-1 or sn-2 position.In the circulation, LPA is in submillimolar range and mainly derived from hydrolysis of lysophosphatidylcholine, a process mediated by lysophospholipase D activity in proteins such as autotaxin (ATX).Intracellular and extracellular LPAs act as bioactive lipid mediators with diverse functions in almost every mammalian cell type.The binding of LPA to its receptors LPA1-6 activates multiple cellular processes such as migration, proliferation and survival.The production of LPA and activation of LPA receptor signaling pathways in the events of physiology and pathophysiology have attracted the interest of researchers.Results from studies using transgenic and gene knockout animals with alterations of ATX and LPA receptors genes, have revealed the roles of LPA signaling pathways in metabolic active tissues and organs.The present review was aimed to summarize recent progresses in the studies of extracellular and intracellular LPA production pathways.This includes the functional, structural and biochemical properties of ATX and LPA receptors.The potential roles of LPA production and LPA receptor signaling pathways in obesity, insulin resistance and liver fibrosis are also discussed.
Lipid mediators in the regulation of endothelial barriers

Pratap Karki,Konstantin G. Birukov

DOI: https://doi.org/10.1080/21688370.2017.1385573

2017-10-30

Tissue Barriers

Abstract:Lipid mediators play a critical role in the development and resolution of vascular endothelial barrier dysfunction caused by various pathologic interventions. The accumulation of excess lipids directly impairs endothelial cell (EC) barrier function that is known to contribute to the development of atherosclerosis and metabolic disorders such as obesity and diabetes as well as chronic inflammation in the vascular endothelium. Certain products of phospholipid oxidation (OxPL) such as fragmented phospholipids generated during oxidative and nitrosative stress show pro-inflammatory potential and cause endothelial barrier dysfunction. In turn, other OxPL products enhance basal EC barrier and exhibit potent barrier-protective effects in pathologic settings of acute vascular leak caused by pro-inflammatory mediators, barrier disruptive agonists and pathologic mechanical stimulation. These beneficial effects were further confirmed in rodent models of lung injury and inflammation. The bioactive oxidized lipid molecules may serve as important therapeutic prototype molecules for future treatment of acute lung injury syndromes associated with endothelial barrier dysfunction and inflammation. This review will summarize recent studies of biological effects exhibited by various groups of lipid mediators with a focus on the role of oxidized phospholipids in control of vascular endothelial barrier, agonist induced EC permeability, inflammation, and barrier recovery related to clinical settings of acute lung injury and inflammatory vascular leak.

Influence of the semiconductive material on space charge build-up in extruded HVDC cables

Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain

The Formation of Phosphatidylcholine Oxidation Products by Stimulated Phagocytes

An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

Lysophosphatidylcholine is a Major Component of Platelet Microvesicles Promoting Platelet Activation and Reporting Atherosclerotic Plaque Instability

Lysophospholipids and Their Receptors Serve As Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury.

Research progress, challenges and perspectives of phospholipids metabolism in the LXR‐LPCAT3 signaling pathway and its relation to NAFLD (Review)

Phospholipase D: a lipid centric review

Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease

Involvement of Lysophospholipids in Pulmonary Vascular Functions and Diseases

Lysophosphatidylcholine facilitates the pathogenesis of psoriasis through activating keratinocytes and T cells differentiation via glycolysis

Phospholipid metabolism in health and disease

The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum

Lysophosphatidylcholine induces cytotoxicity/apoptosis and IL-8 production of human endothelial cells: Related mechanisms

Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis

The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles

Characterization of Lysophospholipase D Activity in Mammalian Cell Membranes

Modified phospholipids as anti-inflammatory compounds

Phosphatidylserine-specific phospholipase A1: A friend or the devil in disguise

Production of Extracellular Lysophosphatidic Acid in the Regulation of Adipocyte Functions and Liver Fibrosis

Lipid mediators in the regulation of endothelial barriers